278 material Form 8-K filings that 243 companies we cover made with the SEC in May 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Primerica reported first quarter 2024 results on May 6, 2024, with diluted earnings per share of $3.93, up 14%, and total revenues of $742.8 million, up 8%. Diluted adjusted operating EPS was $3.91, up 10%, and the company expects a $50 million gain in the second quarter from an insurance claim, which it will exclude from adjusted results. Profit growth is the main takeaway for shareholders, though the Senior Health segment posted a $14 million loss.
Net income of $137.9 million rose 8%; diluted EPS of $3.93 rose 14% from $3.46 a year earlier
Senior Health reported a loss of $14 million; Term Life adjusted operating revenues rose 5% to $440.4 million
Investment and Savings Products sales reached $2.8 billion, up 20%; client asset values ended the quarter at $103 billion
Board declared a $0.75 per share dividend payable June 12, 2024; the company repurchased $109 million of stock in the quarter
J&J Snack Foods reported fiscal second-quarter 2024 results for the period ended March 30, 2024, with net sales of $359.7 million, up 6.5% from a year earlier. Net earnings rose 94.0% to $13.3 million, and diluted EPS was $0.69, and the company said gross margin improved to 30.1%. The results show higher sales and profit for shareholders, though the company also reported $2.3 million in one-time distribution transition costs.
Net sales were $359.7 million, up 6.5%, the highest fiscal second-quarter sales in company history according to management
Net earnings were $13.3 million and diluted EPS was $0.69, compared with $6.9 million and $0.36 in the prior-year quarter
Gross margin rose to 30.1% from 26.8%, and Retail segment sales grew 14.1% to $52.9 million
Results included $2.3 million in one-time transition expenses tied to the Arizona distribution center; a conference call is set for May 7, 2024 at 10:00 a.m. Eastern
Boise Cascade reported first quarter 2024 net income of $104.1 million, or $2.61 per diluted share, on sales of $1.6 billion, compared with $96.7 million, or $2.43 per share, on sales of $1.5 billion a year earlier. Shareholders also elected eleven directors and approved the advisory compensation vote and the KPMG LLP appointment at the May 2, 2024 annual meeting.
Net income $104.1 million, up 8% from $96.7 million; diluted EPS $2.61 vs. $2.43
Sales $1.6 billion ($1,645.4 million), up 7%; Adjusted EBITDA $168.5 million, up 6%
Board declared a quarterly dividend of $0.20 per share on May 2, 2024, payable June 17, 2024
Shareholders elected eleven directors and ratified KPMG LLP as auditor for 2024
Apple Hospitality REIT reported first-quarter 2024 net income of $54 million, up 64% from a year earlier, on total revenue of $329.5 million, up from $311.5 million. The company raised the midpoint of its full-year 2024 net income guidance by $16 million, attributing the increase to its March acquisition of the AC Hotel Washington DC Convention Center. Comparable hotel adjusted EBITDA fell 3.2%, while comparable RevPAR was flat at $111.09.
Q1 2024 net income was $54 million, or $0.22 per share, versus $33 million, or $0.14 per share, in Q1 2023.
Adjusted EBITDAre was $101 million, up 6% from Q1 2023; MFFO was $83 million, up 5%.
2024 net income guidance is $207 million to $233 million, with the midpoint raised by $16 million; Adjusted EBITDAre guidance is $461 million to $483 million, with the midpoint raised by $9 million.
Comparable Hotels Adjusted Hotel EBITDA fell 3.2% to $111.7 million; the company's April 2024 occupancy was approximately 80%.
Artivion reported first-quarter 2024 revenue of $97.4 million, up 17% from $83.2 million a year earlier, and net income of $7.5 million, or $0.18 per diluted share, compared with a net loss of $13.5 million a year earlier. The company raised the low end of its full-year 2024 revenue guidance to $386 million to $396 million, while its adjusted EBITDA forecast of $68 million to $72 million was unchanged.
Q1 2024 revenue $97.4 million, up 17% on a GAAP basis and 16% in constant currency
Net income $7.5 million ($0.18 per diluted share) vs. net loss of $13.5 million ($0.33 per share) in Q1 2023; non-GAAP net income $2.6 million ($0.06 per share)
Non-GAAP adjusted EBITDA rose 60% to $17.3 million from $10.8 million
FY2024 revenue guidance $386 million to $396 million (previously $382 million to $396 million); adjusted EBITDA guidance $68 million to $72 million unchanged
NAPCO reported fiscal third-quarter 2024 results (quarter ended March 31, 2024) with net sales up 13% to $49.3 million and net income up 38% to $13.2 million, or $0.36 per diluted share. The company also announced management changes, including Kevin Buchel's promotion to President and Chief Operating Officer while he remains Chief Financial Officer, and declared a $0.10 per share quarterly dividend.
Net sales rose 13% to $49.3 million; nine-month net sales rose 10% to $138.5 million
Net income rose 38% to $13.2 million ($0.36 per diluted share) versus $9.5 million a year earlier
Kevin Buchel promoted to President and COO effective May 2, 2024, keeping the CFO role; Andrew Vuono appointed SVP of Finance and Chief Accounting Officer, expected to start June 3
Quarterly dividend of $0.10 per share payable June 24, 2024 to holders of record June 3, 2024
Krystal Biotech reported its first quarter 2024 results, its first product revenue after the May 2023 FDA approval of VYJUVEK, with net product revenue of $45.3 million and net income of $0.9 million, or $0.03 per share. A year earlier the company posted a net loss of $45.3 million, or $1.76 per share. The company said it continues to expect $150 million to $175 million of non-GAAP R&D and SG&A expense for 2024.
Net product revenue was $45.3 million for the quarter ended March 31, 2024, with gross margin of 95%.
Net income was $0.9 million, or $0.03 per share, compared with a net loss of $45.3 million, or $1.76 per share, in the first quarter of 2023.
Cash, cash equivalents and investments totaled $622.3 million on March 31, 2024.
The company continues to anticipate $150 million to $175 million of 2024 non-GAAP combined R&D and SG&A expense, excluding stock-based compensation.
Jones Lang LaSalle reported first-quarter 2024 results with revenue of $5.1 billion, up 9% from a year earlier, and net income attributable to common shareholders of $66.1 million, compared with a loss of $9.2 million in the prior-year quarter. Free cash flow was an outflow of $720.7 million, an improvement from the $765.6 million outflow in the first quarter of 2023, while net debt rose from December 31, 2023, which the company attributed to annual incentive compensation payments.
Revenue was $5,124.5 million, up 9% from $4,715.5 million in the first quarter of 2023.
Diluted earnings per share were $1.37, compared with a loss of $0.19; adjusted diluted earnings per share were $1.78, compared with $0.71.
Total net debt was $1,900.8 million at March 31, 2024, up from $1,150.3 million at December 31, 2023, and the company repurchased 110,726 shares for $20.1 million in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.